Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Monday, July 13, 2026 · inc, sana biotechnology

AI Briefing

• Sana Biotechnology announces follow-on publication in NEJM highlighting long-term data on hypoimmune-modified islet cell transplantation.
• The study focuses on Type 1 diabetes treatment without immunosuppression.
• Updated findings are consistent with initial trial data published in NEJM in 2025.

Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025